Nicollet Mall

aTyr Pharma Announces Closing of $86.3 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Monday, September 20, 2021
Sinclair Investments (UK) Ltd v Versailles Trade Finance Ltd, Exercise, RNA transfection, Syndicate, Security (finance), Form S-3, RBC Capital Markets, Sale, LIFE, Attention, U.S. Securities and Exchange Commission, ATyr Pharma, Biology, Form, LLC, SAN, Research, Minnesota, Telephone, Prospectus, Nicollet Mall, SEC, Vesey Street, GLOBE

The gross proceeds to aTyr from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are $86.3 million.

Key Points: 
  • The gross proceeds to aTyr from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are $86.3 million.
  • All of the shares sold in the offering were sold by aTyr.
  • Piper Sandler and RBC Capital Markets acted as joint book-running managers for the offering.
  • The offering was made pursuant effective registration statements, filed by aTyr with the Securities and Exchange Commission ("SEC").

Dutch Bros Inc. Announces Closing of Initial Public Offering, Including Exercise of Underwriters’ Option

Retrieved on: 
Friday, September 17, 2021
Retail, Restaurant, Bar, Convenience Store, Food, Beverage, Madison Avenue, Barclays Capital Inc. v. Theflyonthewall.com, Inc., J.P. Morgan & Co., Exercise, Security (finance), Sale, Attention, U.S. Securities and Exchange Commission, Broadridge Financial Solutions, Company, LLC, BofA Securities, Dutch Bros. Coffee, Telephone, Jefferies Group, Robert W. Baird, Prospectus, Nicollet Mall, Jefferies, New York Stock Exchange, SEC, Mail

Dutch Bros Inc. (Dutch Bros) today announced the closing of its initial public offering of 24,210,526 shares of its Class A common stock, including the exercise in full of the underwriters option to purchase 3,157,894 additional shares, at a price to the public of $23 per share.

Key Points: 
  • Dutch Bros Inc. (Dutch Bros) today announced the closing of its initial public offering of 24,210,526 shares of its Class A common stock, including the exercise in full of the underwriters option to purchase 3,157,894 additional shares, at a price to the public of $23 per share.
  • Proceeds from the initial public offering were approximately $556.8 million, before deducting underwriting discounts and commissions and other offering expenses.
  • The Class A common stock began trading on The New York Stock Exchange (NYSE) under the symbol BROS on September 15, 2021.
  • BofA Securities, J.P. Morgan Securities and Jefferies LLC acted as lead book-running managers and representatives of the underwriters for the offering.

aTyr Pharma Announces Pricing of $75 Million Public Offering of Common Stock

Retrieved on: 
Thursday, September 16, 2021
Form, U.S. Securities and Exchange Commission, Security (finance), Biology, SAN, ATyr Pharma, Syndicate, Nicollet Mall, Forward-looking statement, Prospectus, LIFE, Attention, Private Securities Litigation Reform Act, Vesey Street, LLC, RNA transfection, Annual report, System Floors (UK) Ltd v Daniel, RBC Capital Markets, GLOBE, Form S-3, SEC, Minnesota, Research, Sale, Telephone

The gross proceeds to aTyr from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $75.0 million.

Key Points: 
  • The gross proceeds to aTyr from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $75.0 million.
  • In addition, aTyr has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of its common stock.
  • All of the shares to be sold in the offering are to be sold by aTyr.
  • The offering is being made pursuant effective registration statements, filed by aTyr with the Securities and Exchange Commission ("SEC").

aTyr Pharma Announces Proposed Public Offering of Common Stock

Retrieved on: 
Wednesday, September 15, 2021
Form, U.S. Securities and Exchange Commission, Security (finance), Biology, SAN, ATyr Pharma, Syndicate, Nicollet Mall, Forward-looking statement, Prospectus, LIFE, Attention, Private Securities Litigation Reform Act, Vesey Street, LLC, RNA transfection, S-3, Annual report, RBC Capital Markets, GLOBE, SEC, Minnesota, Research, Sale, Telephone, Pharmaceutical industry

In addition, aTyr expects to grant the underwriters a 30-day option to purchase additional shares of its common stock.

Key Points: 
  • In addition, aTyr expects to grant the underwriters a 30-day option to purchase additional shares of its common stock.
  • All of the shares to be sold in the offering are to be sold by aTyr.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
  • These forward-looking statements include statements regarding the timing, terms and completion of the proposed public offering.

Dutch Bros Inc. Announces Pricing of Initial Public Offering

Retrieved on: 
Tuesday, September 14, 2021
Retail, Restaurant, Bar, Convenience Store, Food, Beverage, U.S. Securities and Exchange Commission, Security (finance), Robert W. Baird, New York Stock Exchange, Nicollet Mall, BofA Securities, Prospectus, Attention, Jefferies, Company, Jefferies Group, Madison Avenue, LLC, Broadridge Financial Solutions, Barclays Capital Inc. v. Theflyonthewall.com, Inc., Dutch Bros. Coffee, J.P. Morgan & Co., SEC, Sale, Telephone, Mail

Dutch Bros Inc. (Dutch Bros) today announced the pricing of its initial public offering of 21,052,632 shares of its Class A common stock at a price to the public of $23.00 per share.

Key Points: 
  • Dutch Bros Inc. (Dutch Bros) today announced the pricing of its initial public offering of 21,052,632 shares of its Class A common stock at a price to the public of $23.00 per share.
  • BofA Securities, J.P. Morgan Securities and Jefferies LLC are acting as lead book-running managers and representatives of the underwriters for the offering.
  • Barclays Capital Inc. and Piper Sandler & Co. are also acting as lead book-running managers for the offering.
  • Founded in 1992 by brothers Dane and Travis Boersma, Dutch Bros began with a double-head espresso machine and a pushcart in Grants Pass, Oregon.

Dutch Bros Inc. Announces Public Filing of Registration Statement for Proposed Initial Public Offering

Retrieved on: 
Friday, August 20, 2021
Company, Nicollet Mall, LLC, U.S. Securities and Exchange Commission, Form, SEC, BROS, William Blair & Company, BofA Securities, Attention, Jefferies Group, Broadridge Financial Solutions, Madison Avenue, Dutch Bros. Coffee, Telephone, NYSE, J.P. Morgan & Co., Multimedia, Prospectus, Barclays Capital Inc. v. Theflyonthewall.com, Inc., New York Stock Exchange, Sale, Sause Bros., Inc., View, Security (finance), Mail

GRANTS PASS, Ore., Aug. 20, 2021 /PRNewswire/ --Dutch Bros Inc. ("Dutch Bros") today announced it has publicly filed a registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of shares of its Class A common stock.

Key Points: 
  • GRANTS PASS, Ore., Aug. 20, 2021 /PRNewswire/ --Dutch Bros Inc. ("Dutch Bros") today announced it has publicly filed a registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of shares of its Class A common stock.
  • The number of shares to be offered and the price range for the proposed offering have not yet been determined.
  • Dutch Bros intends to list its Class A common stock on The New York Stock Exchange ("NYSE") under the symbol "BROS".
  • Robert W. Baird & Co. and William Blair & Company, LLC are acting as book-running managers for the proposed offering.

Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Retrieved on: 
Monday, August 16, 2021
808, SVB Leerink, Fulcrum, U.S. Securities and Exchange Commission, Form, Prospectus, Suite, Company, Montgomery Street, Securities Act of 1933, Therapy, Nicollet Mall, GLOBE, Minnesota, FSHD, SEC, Telephone, Facioscapulohumeral muscular dystrophy, Fetal hemoglobin, Gene expression, Security (finance), Attention, Patient, Sickle cell disease, Exercise, Thalassemia, Sale, State Street, File, Nasdaq

The total gross proceeds of the offering were $144.2 million, before deducting underwriting discounts and commissions and offering expenses payable by Fulcrum.

Key Points: 
  • The total gross proceeds of the offering were $144.2 million, before deducting underwriting discounts and commissions and offering expenses payable by Fulcrum.
  • All of the shares in the offering were sold by Fulcrum.
  • SVB Leerink, Piper Sandler & Co. and Stifel acted as joint bookrunning managers for the offering.
  • This offering was made only by means of a prospectus and prospectus supplement that form a part of the registration statements.

Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock

Retrieved on: 
Thursday, August 12, 2021
808, FSHD, Attention, Fetal hemoglobin, Minnesota, Patient, Thalassemia, Sale, SEC, Therapy, Fulcrum, Form, Gene expression, Facioscapulohumeral muscular dystrophy, Prospectus, File, Nasdaq, Company, GLOBE, State Street, Suite, Private Securities Litigation Reform Act, Security (finance), SVB Leerink, Sickle cell disease, U.S. Securities and Exchange Commission, Industry, Nicollet Mall, Telephone, Securities Act of 1933, Montgomery Street

All of the shares in the offering are being sold by Fulcrum.

Key Points: 
  • All of the shares in the offering are being sold by Fulcrum.
  • In addition, Fulcrum has granted the underwriters a 30-day option to purchase up to 990,000 additional shares of its common stock at the public offering price, less the underwriting discount and commissions.
  • The offering is expected to close on August 16, 2021, subject to customary closing conditions.
  • SVB Leerink, Piper Sandler & Co. and Stifel are acting as joint bookrunning managers for the offering.

Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock

Retrieved on: 
Tuesday, August 10, 2021
808, Telephone, Industry, State Street, Therapy, Gene expression, Company, Patient, FSHD, Prospectus, Facioscapulohumeral muscular dystrophy, Montgomery Street, Attention, Suite, Fulcrum, Nicollet Mall, Sale, Private Securities Litigation Reform Act, Fetal hemoglobin, Nasdaq, Sickle cell disease, SEC, Minnesota, Thalassemia, GLOBE, SVB Leerink, Fine chemical

CAMBRIDGE,Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock.

Key Points: 
  • CAMBRIDGE,Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock.
  • In addition, Fulcrum expects to grant the underwriters a 30-day option to purchase up to an additional $15 million of shares of its common stock.
  • This offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement.
  • There can be no assurance that the Company will be able to complete the proposed public offering on the anticipated terms, or at all.

BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants

Retrieved on: 
Monday, August 9, 2021
BioCryst Pharmaceuticals, Nicollet Mall, Disease, Galidesivir, GLOBE, LLC, Sale, Yellow fever, Nasdaq, RESEARCH, Union, Equity capital markets, PARK, Marburg virus disease, Public expenditure, Telephone, Form, Patient, SEC, Prospectus, United Kingdom, Form S-3, European Union, HAE, U.S. Securities and Exchange Commission, Attention, Annual report, Security (finance), Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., Aug. 09, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that it is offering to sell$200 millionof its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock in an underwritten public offering.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Aug. 09, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that it is offering to sell$200 millionof its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock in an underwritten public offering.
  • As part of this offering, BioCryst intends to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount equal to up to 15% of the securities offered in the public offering.
  • The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
  • J.P. Morgan, Evercore ISI and Piper Sandler are acting as joint book-running managers for the offering.